Background: Asthma is one of the most common chronic diseases in the world by which more than 300 million people are affected. In conventional medicine for asthma treatment, more emphasis is on drug therapy, which has complications and contraindications as well as high costs, so we are investigating to identify the effect of camel’s milk on the symptoms of patients with asthma.
Objective: To examine the effects of camel milk in comparison with standard medicinal therapy on asthma patients.
Methods: This randomized clinical trial was conducted on 46 patients with asthma. The study was conducted in Ghaem Hospital lung clinic in Mashhad, Iran, from May 2016 to November 2017. The participants were randomly divided into control and intervention groups (n, 23 per group) and were assessed both pretreatment and post treatment (before, and three months after treatment). Patients with asthma based on clinical and spirometric criteria were included in the study and divided into two groups of control and intervention. Twenty-three patients with asthma were entered into each group. The control group received routine treatments (steroid and β-agonist inhalation) and the intervention group, which received the usual treatments, plus pasteurized camel milk. Camel milk was administered two times a day (8 am and 8 pm 250 ml without additives). Data were collected using a chronic obstructive pulmonary disease (COPD) assessment test (CAT) questionnaire score and spirometry. The results were analyzed and compared in SPSS version 11.5, using paired t-test, Chi-Square test, and independent sample t-test. The significance level was set at 0.05. 
Results: In this study, changes in the mean of forced expiratory volume during one second (FEV1) measurement and FEV1 percent and CAT questionnaire score in both groups, before and after treatment, were significant. But the mean of FEV1 (measurement and percent) in the intervention group was significantly higher than the control group. The mean of FEV1 percent and FEV1 measurement in the intervention and the control groups were p<0.001, p=0.002, p=0.001 and p=0.049 respectively, while the mean of CAT questionnaire scores were not significantly different between two groups (p<0.001, p<0.001 respectively). In addition, the mean of FEV1 percent and CAT questionnaire score difference in the intervention group were significantly higher than in the control group (p=0.001, p<0.001 respectively), but the mean of FEV1 measurement differences between the intervention and the control group were not significant (p=0.05).
Conclusion: In our study, we found that camel milk, with the standard asthma treatment, would be very helpful. However, there is a need for further studies with a larger sample size on the effect of this nutrient.
Clinical Trial Registration: This study was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the registration code IRCT2016102930541N1.
Funding: This study was supported by Mashhad University of Medical Sciences Research Council, Mashhad, Iran (Ref: 941287). The authors have no conflicts of interest.
Keywords: Asthma, Camel milk, Medicinal therapy


» HTML Fulltext    » PDF Fulltext    » doi: 10.19082/7423
BootsKlær Nike

The  most recent editorial (June 2021)

Ethics of Publishing Case Reports: Do We Need Ethics Approval and Patient Consent?

An editorial by Dr. Mehrdad Jalalian

Read more.

The worldwide spread of COVID-19 as an emerging, rapidly evolving situation, and the dramatic need of urgent medicine or vaccine, has rapidly brought new hypotheses for pathophysiology and potential medicinal agents to the fore. It is crucial that the research community provide a way to publish this research in a timely manner.


To contribute to this important public health discussion, the Electronic Physician Journal is excited to announce a fast-track procedure to help researchers publish their articles on COVID-19 related subjects that fall under the broad definition of public health, internal medicine, and pharmacology. We are especially welcome to all hypotheses about the pathological basis of the COVID-19 infection and the possible characteristics of potential medicine and vaccine. Submit your manuscript here


Our previous editorial (June 2020)

Lessons from COVID-19 pandemic and the Morocco’s success story.

An editorial by Dr. Benksim Abdelhafid (Morocco)

Read more.


The 6th World Conference on Research Integrity (WCRI) is to be held on June 2-5, 2019 in Hong Kong.

The WCRI is the largest and most significant international conference on research integrity. Since the first conference in Lisbon in 2007, it has given researchers, teachers, funding agencies, government officials, journal editors, senior administrators, and research students opportunities to share experiences and to discuss and promote integrity in research. Read more:


TDR Clinical Research and Development Fellowships

Call for applications

Deadline for submission: 7 March 2019, 16:00 (GMT)

TDR provides fellowships for early- to mid-career researchers and clinical trial staff (e.g. clinicians, pharmacists, medical statisticians, data managers, other health researchers) in low- and middle-income countries (LMICs) to learn how to conduct clinical trials. Read more:

Meta-Analysis Workshops in New York, USA, and London, UK, in April and May 2019

Don't miss this exceptional opportunity to learn how to perform and report a Meta-analysis correctly. Two Meta-analysis workshops are organized in April and May 2019 by Dr. Michael Borenstein in New York, USA (April 08-10, 2019) and London, UK (May 27-29).

About the Instructor

Dr. Michael Borenstein, one of the authors of Introduction to Meta-Analysis, is widely recognized for his ability to make statistical concepts accessible to researchers as well as to statisticians. He has lectured widely on meta-analysis, including at the NIH, CDC, and FDA. Read more: